Therefore, D2-HG has been considered as an oncometabolite [192] and its production could be an efficient strategy to identify the IDH1/2 mutated subset of patients with malignant gliomas, as shown by Choi et al., who used MRS to detect D2-HG in 30 glioma patients and proved that this noninvasive diagnostic tool could be powerful to apply clinically [196]. This evidence concerns the gene IDH1 and glioma.